ASH 2022 | Targeting the T315I mutation with ponatinib to treat patients with R/R Ph+ ALL
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the challenges in treating relapsed/refractory (R/R) Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Dr Short explains that Ph+ R/R ALL is often driven by mutations in the ABL1 gene, and in particular the T315I mutation, which usually arises when patients are treated with first- and second-generation tyrosine kinase inhibitors (TKIs). To overcome this challenge, Dr Short highlights the role of ponatinib in this setting, and believes that combining this TKI with other agents may be a viable option for treating patients with Ph+ R/R ALL. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy; Astellas: Research Funding; Takeda Oncology: Consultancy, Research Funding; Pfizer: Consultancy; Stemline Therapeutics: Research Funding; AstraZeneca: Consultancy; Amgen: Consultancy, Honoraria.
